SCHEMBL3387448

SCHEMBL3387448

NC(c1ccccn1)c1ncnc2scc(-c3cccc(F)c3)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2C Q8TBX8 5/20 0.46
HTT P42858 3/20 0.46
MITF O75030 1/20 0.46
PAX8 Q06710 1/20 0.46
FGFR1 P11362 3/20 0.43
DAPK3 O43293 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
ABL1 P00519 1/20 0.43
NTRK1 P04629 1/20 0.43
LCK P06239 1/20 0.43
CSF1R P07333 1/20 0.43
RET P07949 1/20 0.43
MET P08581 1/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
PRKACA P17612 1/20 0.43
FLT1 P17948 1/20 0.43
LTK P29376 1/20 0.43
KDR P35968 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3382727 0.88 KDR (0.41) PIP4K2CHTTFGFR1DAPK3PRKD3
SCHEMBL3387950 0.88 LMNA (0.52) PIP4K2CHTTMITFPAX8FGFR1
SCHEMBL2369059 0.88 FGFR1 (0.56) HTTFGFR1DAPK3PRKD3MAP4K4
SCHEMBL3385844 0.87 PIP4K2C (0.46) PIP4K2CHTTFGFR1DAPK3PRKD3
SCHEMBL3387850 0.85 FGFR1 (0.51) PIP4K2CHTTMITFFGFR1DAPK3
SCHEMBL3381240 0.83 LMNA (0.48) PIP4K2CHTTFGFR1DAPK3PRKD3
SCHEMBL3385743 0.81 HTT (0.54) PIP4K2CHTTFGFR1DAPK3PRKD3
SCHEMBL3384944 0.81 FGFR1 (0.37) PIP4K2CHTTPAX8FGFR1DAPK3
SCHEMBL3388361 0.80 SMN1; SMN2 (0.37) PIP4K2CHTTPAX8FGFR1DAPK3
SCHEMBL2368448 0.80 HTT (0.47) PIP4K2CHTTPAX8FGFR1DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 PIP4K2C 2695/4885HTT 543/4885MITF 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.